This document is a summary of the European public assessment report (EPAR) for Thelin. It explains how the Committee for Medicinal Products for Human Use (CHMP) ssessed the medicine to reach its
improve exercise capacity (the ability to carry out physical activity). PAH is abnormally high blood pressure in the arteries of the lungs. Thelin is used in patients with class III disease. The ‘class’ reflects the seriousness of the disease: ‘class III’ involves marked limitation of physical activity. Thelin has been shown to be effective in PAH with no identified cause and PAH caused by connective tissue
Because the number of patients with pulmonary arterial hypertension is low, the disease is considered ‘rare’, and Thelin was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 October 2004.
The medicine can only be obtained with a prescription.
How is Thelin used?
Thelin should only be started and monitored by a doctor who has experience in the treatment of PAH.
© European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged.
It is taken as one tablet a day, preferably at the same time of the day. This is the maximum dose. If after 12 weeks the patient’s condition is getting worse, then the doctor should review the treatment.
How does Thelin work?